Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Maryland & EDMONTON, Alberta–(BUSINESS WIRE)–
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress.

Financial Results

  • Total Revenue: For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025.
    • Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025.
    • License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026, license, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was $4.1 million, up 64% from $2.5 million in the same period of 2025.
  • Net Income: For the three months ended March 31, 2026, net income was $34.4 million, up 48% from $23.3 million in the same period of 2025.
  • Diluted Earnings per Share: For the three months ended March 31, 2026, diluted earnings per share was $0.25, up 56% from $0.16 in the same period of 2025.
  • Cash Flows from Operating Activities: For the three months ended March 31, 2026, cash flows from operating activities were $32.6 million, up 2408% from $1.3 million in the same period of 2025.

Cash Position

As of March 31, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $378.8 million, compared to $398.0 million at December 31, 2025. For the three months ended March 31, 2026, cash outflows from financing activities were $53.7 million, which included the repurchase of 2.5 million of the Company’s common shares for $36.2 million and tax withholding payments related to net settlements of equity awards of $14.6 million.

2026 Total Revenue and Net Product Sales Guidance

Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.

“Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases,” stated Kevin Tang, Chief Executive Officer. “LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders.”

About Aurinia

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 

 

March 31,

2026

December 31,

2025

 

(Unaudited)

 

ASSETS

 

 

Current assets:

 

 

Cash, cash equivalents and restricted cash

$

41,008

 

$

80,213

 

Short-term investments

 

337,775

 

 

317,784

 

Accounts receivable, net

 

49,175

 

 

41,454

 

Inventory

 

46,410

 

 

45,690

 

Prepaid expenses and deposits

 

4,119

 

 

5,746

 

Other current assets

 

1,757

 

 

1,080

 

Total current assets

 

480,244

 

 

491,967

 

Deferred tax assets, net

 

166,917

 

 

176,194

 

Finance right-of-use lease assets

 

69,508

 

 

73,865

 

Intangible assets, net

 

3,590

 

 

3,761

 

Operating right-of-use lease assets

 

1,659

 

 

3,596

 

Property and equipment, net

 

1,986

 

 

2,111

 

Other noncurrent assets

 

93

 

 

93

 

Total assets

$

723,997

 

$

751,587

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

Current liabilities:

 

 

Accounts payable

$

2,661

 

$

3,313

 

Accrued expenses

 

58,196

 

 

66,621

 

Finance lease liabilities, current portion

 

16,519

 

 

16,523

 

Deferred revenue

 

5,036

 

 

3,720

 

Operating lease liabilities, current portion

 

1,622

 

 

1,067

 

Other current liabilities

 

2,522

 

 

2,480

 

Total current liabilities

 

86,556

 

 

93,724

 

Finance lease liabilities, less current portion

 

48,181

 

 

52,322

 

Deferred revenue, less current portion

 

12,413

 

 

12,648

 

Deferred compensation and other noncurrent liabilities

 

6,903

 

 

6,662

 

Operating lease liabilities, less current portion

 

2,318

 

 

4,900

 

Total liabilities

 

156,371

 

 

170,256

 

Shareholders’ equity

 

 

Common shares — no par value, unlimited shares authorized, 130,771 and 132,323 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

 

 

 

1,086,650

 

 

 

 

 

1,120,035

 

 

Additional paid-in capital

 

96,869

 

 

111,263

 

Accumulated other comprehensive loss

 

(880

)

 

(599

)

Accumulated deficit

 

(615,013

)

 

(649,368

)

Total shareholders’ equity

 

567,626

 

 

581,331

 

Total liabilities and shareholders’ equity

$

723,997

 

$

751,587

 

 

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)

 

Three Months Ended

March 31,

 

2026

2025

Revenue

 

 

Net product sales

$

73,563

 

$

59,971

 

License, collaboration and royalty revenue

 

4,142

 

 

2,494

 

Total revenue

 

77,705

 

 

62,465

 

Operating expenses

 

 

Cost of revenue

 

6,505

 

 

8,574

 

Selling, general and administrative

 

22,029

 

 

20,339

 

Research and development

 

7,470

 

 

5,743

 

Restructuring

 

 

 

1,533

 

Other expense, net

 

279

 

 

4,429

 

Total operating expenses

 

36,283

 

 

40,618

 

Income from operations

 

41,422

 

 

21,847

 

Interest income

 

3,515

 

 

3,569

 

Interest expense

 

(1,012

)

 

(1,067

)

Net income before income taxes

 

43,925

 

 

24,349

 

Income tax expense

 

9,570

 

 

1,005

 

Net income

$

34,355

 

$

23,344

 

 

 

 

Earnings per share

 

 

Basic

$

0.26

 

$

0.17

 

Diluted

$

0.25

 

$

0.16

 

 

 

 

Shares used in computing earnings per share

 

 

Basic

 

132,375

 

 

138,917

 

Diluted

 

137,639

 

 

143,199

 

 

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

 

Three Months Ended

March 31,

 

2026

2025

Cash flows from operating activities:

 

 

Net income

$

34,355

 

$

23,344

 

Adjustments to reconcile net income to cash flows from operating activities:

 

 

Deferred income tax

 

9,277

 

 

 

Share-based compensation

 

(866

)

 

(3,409

)

Amortization and depreciation

 

4,816

 

 

4,856

 

Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability

 

(416

)

 

1,812

 

Net amortization of premiums and discounts on investments

 

(2,319

)

 

(2,656

)

Other, net

 

581

 

 

2,325

 

Net changes in operating assets and liabilities:

 

 

Accounts receivable, net

 

(7,721

)

 

(3,806

)

Inventory

 

(720

)

 

(6,967

)

Prepaid expenses and other current assets

 

950

 

 

6,033

 

Accounts payable

 

(652

)

 

(974

)

Accrued expenses and other liabilities

 

(5,592

)

 

(23,405

)

Deferred revenue

 

1,081

 

 

4,342

 

Operating lease liabilities

 

(214

)

 

(195

)

Cash flows from operating activities

 

32,560

 

 

1,300

 

Cash flows from investing activities:

 

 

Proceeds from the sale and maturities of investments

 

109,000

 

 

123,035

 

Purchases of investments

 

(127,041

)

 

(91,986

)

Purchases of property, equipment and intangible assets

 

(39

)

 

(17

)

Cash flows from investing activities

 

(18,080

)

 

31,032

 

Cash flows from financing activities:

 

 

Purchase of common shares under Share Repurchase Plan

 

(36,165

)

 

(46,921

)

Payments of principal portion of Monoplant finance lease liability

 

(3,653

)

 

(2,771

)

Proceeds from issuance of common shares for equity awards

 

713

 

 

9,288

 

Tax withholding payments related to net settlements of equity awards

 

(14,580

)

 

(8,933

)

Cash flows from financing activities

 

(53,685

)

 

(49,337

)

Net decrease in cash, cash equivalents and restricted cash

 

(39,205

)

 

(17,005

)

Cash, cash equivalents and restricted cash, beginning of the period

 

80,213

 

 

83,433

 

Cash, cash equivalents and restricted cash, end of the period

$

41,008

 

$

66,428

 

 

General Investor Inquiries

[email protected]

KEYWORDS: Maryland United States North America Canada

INDUSTRY KEYWORDS: Health Clinical Trials Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo

Fresh Del Monte Names Pittsburgh as New Hub for Foods Division

Fresh Del Monte Names Pittsburgh as New Hub for Foods Division

Del Monte Foods, recently acquired by Fresh Del Monte, has a long history in the Steel City and will continue operating there

PITTSBURGH–(BUSINESS WIRE)–Del Monte Foods, Inc., a division of Fresh Del Monte Produce Inc., one of the world’s leading vertically integrated producers, distributors and marketers of fresh and shelf-stable produce, today reaffirmed its long-standing connection to Pittsburgh by making the city its central hub.

“Pittsburgh has been an important part of our story for more than two decades,” said Mohammad Abu-Ghazaleh, Fresh Del Monte Chairman and Chief Executive Officer. “As we look ahead, we are proud to deepen our presence here while continuing to invest in the people, partnerships and community that have supported us over the years.”

Del Monte Food’s history in Pittsburgh dates back to 2002, when the company acquired several iconic brands—including StarKist, 9Lives, and Nature’s Goodness—from Heinz. In 2021, Del Monte Foods relocated its Pittsburgh offices from the North Shore to Penn Center West in Robinson Township, marking a new chapter in its regional footprint while maintaining strong ties to the local community.

More than two decades later, the company’s Foods division is proud to call Pittsburgh its operational hub. In the near term, core functions for the Foods division—including supply chain, finance, commercial operations and research and development—will be anchored in the city. Notably, the presence of senior leadership in Pittsburgh marks a meaningful evolution, reinforcing the city’s role at the center of the division’s next chapter.

About Fresh Del Monte Produce Inc.

Fresh Del Monte Produce Inc. is a leading global producer, marketer, and distributor of high-quality fresh, fresh-cut, and prepared fruit and vegetables, with products sold in more than 90 countries worldwide. The company also operates a growing global platform across fresh, refrigerated, and shelf-stable food categories. Fresh Del Monte markets its products worldwide under the DEL MONTE® brand and other recognized brands, a symbol of quality, innovation, freshness, and reliability for more than 140 years. The company owns global rights to the Del Monte® brand, subject to certain existing licensing arrangements. Fresh Del Monte Produce Inc. is not affiliated with certain other Del Monte companies around the world, including Del Monte Asia Pte. Ltd. Fresh Del Monte is the first global marketer of fruits and vegetables to commit to the Science Based Targets initiative. The company has been recognized as one of America’s Most Trusted Companies by Newsweek and named a Humankind 100 Company by Humankind Investments. Fresh Del Monte Produce Inc. is traded on the New York Stock Exchange under the symbol FDP.

Media Contacts:

Havas Formula

[email protected]

Claudia Pou

Vice President, Global Head of Corporate Communications

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Agriculture Natural Resources Supermarket Packaging Supply Chain Management Food/Beverage Manufacturing Retail

MEDIA:

Logo
Logo

APi Group Announces Launch of $500 Million Senior Notes Offering and Intent to Amend and Extend Existing Credit Agreement

APi Group Announces Launch of $500 Million Senior Notes Offering and Intent to Amend and Extend Existing Credit Agreement

NEW BRIGHTON, Minn.–(BUSINESS WIRE)–
APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced the launch of a $500 million senior unsecured notes offering (the “Notes”), subject to market and other customary conditions. The Notes will be senior unsecured obligations of APi Group DE, Inc. (“APi DE”), a wholly owned subsidiary of the Company, and will be fully and unconditionally guaranteed on a senior unsecured basis by the Company and certain of the Company’s existing and future foreign and domestic subsidiaries. Concurrently, APi intends to amend the Company’s existing credit agreement (the “Amendment”) to extend the maturity of the Company’s Term Loan B facility to 2033, upsize and extend the Company’s revolving credit facility to $1.0 billion, maturing in 2031, and amend other key terms and covenants. APi intends to use the net proceeds from these financings for funding of the recently signed and announced Onyx-Fire Protection Services Inc. and Wtech Fire Group acquisitions, as well as for general corporate purposes.

The Notes are being offered in a private offering solely to parties reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons in accordance with Regulation S under the Securities Act. No assurance can be given that the offering of the Notes or the Amendment will be completed, or, if completed, as to the terms on which it will be completed. This release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements.

About APi:

APi is a global, market-leading business services provider of fire and life safety, security, elevator and escalator, and specialty services with a substantial recurring revenue base and over 500 locations worldwide. APi provides statutorily mandated and other contracted services to a strong base of long-standing customers across industries. APi has a winning leadership culture driven by entrepreneurial business leaders delivering innovative solutions for customers. More information can be found at www.apigroupinc.com.

Investor Relations and Media Inquiries:

Adam Walters

Senior Director of Investor Relations

Tel: +1 920-419-5432

Email: [email protected]

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Public Policy/Government Law Enforcement/Emergency Services Other Construction & Property Manufacturing Construction & Property Building Systems Other Manufacturing

MEDIA:

Logo
Logo

LegalZoom Reinvents Virtual Mail with AI to Help Small Businesses Save Time and Protect Privacy

LegalZoom Reinvents Virtual Mail with AI to Help Small Businesses Save Time and Protect Privacy

LegalZoom Virtual Mail service has helped businesses process nearly 18 million pieces of mail, including 1.7 million checks representing $9.5 billion in deposits

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–
LegalZoom (Nasdaq: LZ), America’s #1 online legal services company, today announced a major reinvention of LegalZoom Virtual Mail service for business customers. The updated and enhanced offering combines LegalZoom’s trusted legal and compliance solutions with a best-in-class AI-powered digital mailroom, giving business customers a cleaner, faster way to protect their privacy, manage postal mail from any device, and reclaim lost time. Most of the largest AI companies use LegalZoom Virtual Mail.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507872226/en/

LegalZoom Virtual Mail enhanced with AI.

LegalZoom Virtual Mail enhanced with AI.

The reimagined Virtual Mail service significantly enhances efficiency and productivity. Advanced AI-powered features automatically filter unwanted mail, categorize important documents, and generate instant summaries, allowing business owners to save time and focus on higher-value work. These innovations are particularly valuable for businesses seeking to operate more effectively without increasing administrative overhead.

“With our improved Virtual Mail experience, we’re making it easier than ever for business owners to safeguard their privacy while leveraging powerful digital tools, including AI, to manage their physical mail and streamline critical business communications,” said Aaron Stibel, LegalZoom Chief Business & Customer Officer. “This is the kind of innovation that makes a real difference for entrepreneurs who are trying to do more with less.”

The enhanced experience reinforces LegalZoom’s commitment to helping customers keep their personal home addresses more private, thereby protecting their identity and their professional image. This focus on privacy is paired with the company’s long-standing reputation for trust and convenience. Users can access their mail from anywhere while LegalZoom handles sorting, scanning, and digital delivery in its secure facilities, freeing them from physical mail management.

A standout addition to the LegalZoom Virtual Mail service is a new automated Check Separation feature, which allows customers to split multiple checks from a single mail item and deposit into separate accounts. The Check Separation feature offers smart detection, self-service via the app, unified processing in one tool, and instant customer notifications. It also eliminates the need for middlemen and provides real-time speed, thereby streamlining a previously labor-intensive and complicated process for businesses of all sizes.

Since its inception, LegalZoom’s Virtual Mail service has helped business customers process 17.8 million pieces of mail. Notably, the platform has processed 1.7 million checks to date, representing a total of $9.5 billion in check deposits, underscoring the scale and trust businesses place in LegalZoom’s mailroom solution.

LegalZoom Virtual Mail serves businesses at every stage. New founders and solopreneurs can use it to keep their home address more private and project a professional image from day one. Small business owners can use it to conveniently access and manage mail online so they don’t waste time or miss anything critical. Mid-market companies can use it to process, organize, and distribute mail digitally so their teams can operate efficiently and securely.

To learn more, visit LegalZoom.com/VirtualMail.

About LegalZoom

LegalZoom is a leading online platform for legal services, transforming how individuals and small businesses navigate the legal system. By combining intuitive technology with access to experienced attorneys—whether through our vast independent attorney network or our own law firm—we offer the tools and guidance people need to confidently manage everything from business formation and compliance to intellectual property protection and ongoing business management and legal support.

As AI reshapes how legal work gets done, LegalZoom is at the forefront of the human-in-the-loop approach, ensuring that the speed and efficiency of AI is always backed by the judgment and accountability of qualified professionals. With over two decades of experience and millions of customers served, LegalZoom helps individuals and small businesses navigate legal needs with confidence. For more information, please visit www.legalzoom.com.

Investor Relations

[email protected]

Press

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Banking Professional Services Fintech Payments Apps/Applications Technology Small Business Artificial Intelligence Legal Finance Other Technology

MEDIA:

Photo
Photo
LegalZoom Virtual Mail enhanced with AI.
Logo
Logo

Marcus & Millichap, Inc. Reports Preliminary Results for First Quarter 2026

Marcus & Millichap, Inc. Reports Preliminary Results for First Quarter 2026

Revenue growth of 18.2% in the First Quarter 2026 compared to First Quarter 2025.

CALABASAS, Calif.–(BUSINESS WIRE)–
Marcus & Millichap, Inc. (the “Company”, “Marcus & Millichap”, or “MMI”) (NYSE: MMI), a leading national real estate services firm specializing in commercial real estate investment sales, financing services, research and advisory services, reported its first quarter financial results today.

First Quarter 2026 Highlights Compared to First Quarter 2025

  • Total revenue of $171.5 million, an increase of 18.2% compared to $145.0 million

    • Brokerage commissions of $138.1 million, an increase of 11.7% compared to $123.6 million

    • Private Client Market brokerage revenue of $88.1 million, an increase of 13.4% compared to $77.7 million

    • Middle Market and Larger Transaction Market brokerage revenue of $44.6 million, an increase of 9.2% compared to $40.9 million

    • Financing fees of $26.8 million, an increase of 48.1% compared to $18.1 million

  • Pre-tax loss of $2.2 million compared to $13.9 million, an improvement of 84.4%

  • Net loss of $3.1 million, or $0.08 per common share, diluted, compared to a net loss of $4.4 million, or $0.11 per common share, diluted

  • Adjusted EBITDA1 of $2.9 million compared to $(8.7) million, an improvement of 133.7%.

“We delivered a strong first quarter, with broad-based growth across the business, reflecting investments in talent, business development and platform expansion as well as improving market conditions,” said Hessam Nadji, President and Chief Executive Officer of Marcus & Millichap. “Our Private Client business continued to build momentum while our institutional segment also posted gains as bid/ask spreads narrowed due to gradual price adjustments and improvements in the lending environment. Our financing business had an exceptional quarter as capital availability grew and we leveraged our market leading lender network to achieve revenue growth of 48%.”

Mr. Nadji continued, “We are encouraged by the improvement we are seeing and the fundamentals supporting continued recovery – driven by more realistic pricing and an increasingly liquid credit environment. Geopolitical developments and energy price volatility have introduced near-term uncertainty, which we are navigating with the same discipline that has served us well through the extended market disruption. Our strong balance sheet and broad capital deployment plan enabled us to accelerate share buybacks while continuing our dividend policy and having ample capital for strategic acquisitions and platform investments.”

 
1 Please refer to the reconciliation of U.S. GAAP measures to non-GAAP measures at the end of this release for more information.

First Quarter 2026 Results Compared to First Quarter 2025

Total revenue for the first quarter 2026 was $171.5 million, an increase of 18.2% compared to $145.0 million for the first quarter 2025.

For real estate brokerage commissions, revenue was $138.1 million, an increase of 11.7% compared to the same period in the prior year. The increase was primarily attributed to an 18.5% increase in total sales volume, partially offset by an 11 basis point decrease in the average commission rate earned compared to the first quarter 2025. The decrease in the average commission rate was due to revenue shifting from the Private Client Market to the Larger Transaction Market, which generally earns lower commission rates. The Larger Transaction Market revenue increased by 24.9%, while the Private Client Market revenue increased by 13.4%.

For financing fees, revenue was $26.8 million, an increase of 48.1% compared to the same period in the prior year. The increase was primarily attributed to a 60.1% increase in total financing volume, partially offset by a four basis point decrease in the average fee rate earned, compared to the first quarter 2025.

Total operating expenses for the first quarter 2026 were $177.2 million compared to $162.7 million for the same period in the prior year. The change was primarily due to an increase of $15.3 million in cost of services. Cost of services as a percentage of total revenue decreased by 40 basis points to 60.5% compared to the same period during the prior year, primarily due to our senior investment sales and financing professionals earning higher commissions in 2025.

Selling, general and administrative expenses remained relatively consistent at $71.2 million for the first quarter 2026 compared to $71.6 million for the same period in 2025.

Net loss for the first quarter 2026 was $3.1 million, or $0.08 per common share, diluted, compared to a net loss of $4.4 million, or $0.11 per common share, diluted, for the same period in 2025. Adjusted EBITDA for the first quarter 2026 was $2.9 million, compared to $(8.7) million for the same period in the prior year, primarily as a result of the decrease in operating losses.

Capital Allocation

On February 10, 2026, the Board of Directors declared a semi-annual regular dividend of $0.25 per share, which was paid on April 3, 2026, to stockholders of record at the close of business on March 13, 2026.

During the three months ended March 31, 2026, the Company repurchased 895,532 shares of common stock at an average price of $26.22 for a total purchase price of $23.5 million. Since August 2022, the Company has repurchased and retired 3,970,069 shares of common stock at an average price of $30.08 per share for a total price of $119.4 million.

On April 30, 2026, the Company’s Board of Directors approved an additional $70 million to repurchase common stock under its stock repurchase program. After accounting for shares repurchased through May 4, 2026 and the increased authorization, the Company has approximately $90 million available to repurchase shares under its program. No time limit has been established for the completion of the program, and the repurchases are expected to be executed from time to time, subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans.

Business Outlook

Despite ongoing price discovery and wider than normal bid/ask spreads, the Company believes the commercial real estate transaction market is poised to overcome the near-term challenges which are currently expected to extend through 2026. Accordingly, the Company believes it remains well-positioned to return to long-term growth.

The Company benefits from its experienced management team, infrastructure investments, industry-leading market research and proprietary technology. The size and fragmentation of the Private Client Market continue to offer long-term growth opportunities through consolidation. This highly fragmented market segment consistently accounts for over 80% of all U.S. commercial property transactions and over 60% of the commission pool. The top 10 brokerage firms led by MMI had an estimated 18% share of this segment by transaction count in 2025.

Key factors that may influence the Company’s business during the remainder of 2026 include:

  • Volatility in transactional activity and investor sentiment driven by:

    • potentially volatile cost of debt capital;

    • interest rate uncertainty, the potential for rising inflation and the heightened bid-ask spread between buyers and sellers;

    • risks of a potential recession and its unfavorable impact on commercial real estate space demand;

    • possible impact of the U.S. administration’s tariff, immigration, geopolitics and other policy changes on market sentiment, which may influence transaction velocity and/or future fluctuations in interest rates, sales and financing activity; and

    • increases in operating expenses driven by labor costs, insurance, taxes and cost of construction materials.

  • The implementation of new tax laws, many of which are beneficial to commercial real estate investors;

  • Volatility in the markets in which the Company operates;

  • Increases in costs related to in-person events, client meetings, and conferences;

  • Global geopolitical uncertainty, which may cause investors to refrain from transacting; and

  • The potential for acquisition activity and subsequent integration.

Webcast and Call Information

Marcus & Millichap will host a live webcast today to discuss the financial results at 7:30 a.m. Pacific Time/10:30 a.m. Eastern Time. The webcast will be accessible through the Investor Relations section of Marcus & Millichap’s website at ir.marcusmillichap.com and will be archived upon completion of the call. The Company encourages the use of the webcast due to potential extended wait times to access the conference call via dial-in.

For those unable to access the webcast, callers from the United States and Canada should dial 1-877-407-9208 ten minutes prior to the scheduled call time. International callers should dial 1-201-493-6784.

ReplayInformation

For those unable to participate during the live broadcast, a telephonic replay of the call will also be available from 1:30 p.m. Eastern Time on Thursday, May 7, 2026 through 11:59 p.m. Eastern Time on Thursday, May 21, 2026 by dialing 1-844-512-2921 in the United States and Canada or 1-412-317-6671 internationally and entering passcode 13759354.

About Marcus & Millichap, Inc.

Marcus & Millichap, Inc. is a leading national real estate services firm specializing in commercial real estate investment sales, financing services, research and advisory services. As of December 31, 2025, the Company had 1,808 investment sales and financing professionals in more than 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate. The Company also offers market research, consulting and advisory, and leasing services to its clients. Marcus & Millichap, Inc. closed 8,818 transactions in 2025, with a sales volume of $50.8 billion. For additional information, please visit www.MarcusMillichap.com.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements, including our expectations regarding the long-term outlook of the commercial real estate transaction market, and our positioning within it, our belief relating to the Company’s long-term growth, our assessment of the key factors influencing the Company’s business outlook, including the expectation for future interest rate cuts or rising inflation and likely impact of such cuts or inflation on commercial real estate demand, and the execution of our capital return program, including a semi-annual dividend and stock repurchase program. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results may be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

  • general uncertainty in the capital markets, a worsening of economic conditions, and the rate and pace of economic recovery following an economic downturn;

  • changes in our business operations;

  • market trends in the commercial real estate market or the general economy, including the impact of inflation and changes to interest rates;

  • our ability to attract and retain qualified senior executives, managers, and investment sales and financing professionals;

  • the impact of forgivable loans and related expense resulting from the recruitment and retention of agents;

  • the impact of litigation and our success in appealing any judgments entered against us;

  • the effects of increased competition on our business;

  • our ability to successfully enter new markets or increase our market share;

  • our ability to successfully expand our services and businesses and to manage any such expansions;

  • our ability to retain existing clients and develop new clients;

  • our ability to keep pace with changes in technology;

  • any business interruption or technology failure, including cybersecurity risks and ransomware attacks, and any related impact on our brand reputation or clients;

  • changes in interest rates, availability of capital, tax laws, tariffs and trade regulations, executive orders, employment laws, or other government regulation affecting our business;

  • our ability to successfully identify, negotiate, execute, and integrate accretive acquisitions; and

  • other risk factors included under “Risk Factors” in our most recent Annual Report on Form 10-K or in any subsequent SEC report.

In addition, in this release, words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “goal,” “expect,” “predict,” “potential,” “should,” and similar expressions, as they relate to our Company, our business and our management, are intended to identify forward-looking statements. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.

Forward-looking statements speak only as of the date of this release. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We have not filed our Quarterly Report on Form 10-Q (“Form 10-Q”) for the quarter ended March 31, 2026. As a result, all financial results described in this release should be considered preliminary, and are subject to change to reflect any necessary adjustments or changes in accounting estimates, that are identified prior to the time we file our Form 10-Q.

MARCUS & MILLICHAP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

 

 

Three Months Ended

March 31,

 

2026

 

2025

Revenue:

 

 

 

Real estate brokerage commissions

$

138,112

 

 

$

123,622

 

Financing fees

 

26,846

 

 

 

18,130

 

Other revenue

 

6,509

 

 

 

3,286

 

Total revenue

 

171,467

 

 

 

145,038

 

Operating expenses:

 

 

 

Cost of services

 

103,637

 

 

 

88,348

 

Selling, general and administrative

 

71,215

 

 

 

71,552

 

Depreciation and amortization

 

2,391

 

 

 

2,849

 

Total operating expenses

 

177,243

 

 

 

162,749

 

Operating loss

 

(5,776

)

 

 

(17,711

)

Other income, net

 

3,763

 

 

 

3,979

 

Interest expense

 

(153

)

 

 

(187

)

Loss before benefit for income taxes

 

(2,166

)

 

 

(13,919

)

Provision (benefit) for income taxes

 

934

 

 

 

(9,497

)

Net loss

$

(3,100

)

 

$

(4,422

)

 

 

 

 

Loss per share:

 

 

 

Basic

$

(0.08

)

 

$

(0.11

)

Diluted

$

(0.08

)

 

$

(0.11

)

Weighted average common shares outstanding:

 

 

 

Basic

 

38,201

 

 

 

38,930

 

Diluted

 

38,201

 

 

 

38,930

 

MARCUS & MILLICHAP, INC.

KEY OPERATING METRICS SUMMARY

(Unaudited)

Total sales volume was approximately $12.1 billion for the three months ended March 31, 2026, encompassing 2,022 transactions consisting of $7.9 billion for real estate brokerage (1,348 transactions), $3.1 billion for financing (398 transactions) and $1.1 billion in other transactions, including consulting and advisory services (276 transactions). As of March 31, 2026, the Company had 1,621 investment sales professionals and 103 financing professionals. Key metrics for real estate brokerage and financing activities (excluding other transactions) are as follows:

 

Three Months Ended

March 31,

Real Estate Brokerage

2026

 

2025

Average number of investment sales professionals

 

1,636

 

 

 

1,578

 

Average number of transactions per investment sales professional

 

0.82

 

 

 

0.74

 

Average commission per transaction

$

102,457

 

 

$

105,210

 

Average commission rate

 

1.75

%

 

 

1.86

%

Average transaction size (in thousands)

$

5,854

 

 

$

5,668

 

Total number of transactions

 

1,348

 

 

 

1,175

 

Total brokerage sales volume (in millions)

$

7,891

 

 

$

6,659

 

 

Three Months Ended

March 31,

Financing (1)

2026

 

2025

Average number of financing professionals

 

101

 

 

 

102

 

Average number of transactions per financing professional

 

3.94

 

 

 

3.30

 

Average fee per transaction

$

55,187

 

 

$

42,702

 

Average fee rate

 

0.71

%

 

 

0.75

%

Average transaction size (in thousands)

$

7,754

 

 

$

5,721

 

Total number of transactions

 

398

 

 

 

337

 

Total financing sales volume (in millions)

$

3,086

 

 

$

1,928

 

(1)

Operating metrics exclude certain financing fees not directly associated to transactions.

The following table sets forth the number of transactions, sales volume and revenue by commercial real estate market for real estate brokerage:

 

Three Months Ended March 31,

 

 

 

2026

 

2025

 

Change

Real Estate Brokerage

Number

 

Volume

 

Revenue

 

Number

 

Volume

 

Revenue

 

Number

 

Volume

 

Revenue

 

 

 

(in millions)

 

(in thousands)

 

 

 

(in millions)

 

(in thousands)

 

 

 

(in millions)

 

(in thousands)

<$1 million

201

 

$

118

 

$

5,335

 

199

 

$

123

 

$

5,026

 

2

 

 

$

(5

)

 

$

309

 

Private Client Market

($1 – <$10 million)

990

 

 

3,283

 

 

88,137

 

832

 

 

2,688

 

 

77,705

 

158

 

 

 

595

 

 

 

10,432

 

Middle Market

($10 – <$20 million)

80

 

 

1,038

 

 

19,656

 

85

 

 

1,202

 

 

20,889

 

(5

)

 

 

(164

)

 

 

(1,233

)

Larger Transaction Market (≥$20 million)

77

 

 

3,452

 

 

24,984

 

59

 

 

2,646

 

 

20,002

 

18

 

 

 

806

 

 

 

4,982

 

 

1,348

 

$

7,891

 

$

138,112

 

1,175

 

$

6,659

 

$

123,622

 

173

 

 

$

1,232

 

 

$

14,490

 

MARCUS & MILLICHAP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for shares and par value)

 

 

March 31, 2026

(unaudited)

 

December 31,

2025

Assets

 

 

 

Current assets:

 

 

 

Cash, cash equivalents, and restricted cash (restricted cash of $11,488 and $11,253 at March 31, 2026 and December 31, 2025, respectively)

$

136,509

 

 

$

161,921

Commissions receivable

 

12,750

 

 

 

14,851

Prepaid expenses

 

9,908

 

 

 

10,424

Income tax receivable

 

802

 

 

 

1,962

Marketable debt securities, available-for-sale (amortized cost of $56,560 and $90,557 at

 

March 31, 2026 and December 31, 2025, respectively, and $0 allowance for credit losses)

 

56,527

 

 

 

90,564

Advances and loans, net

 

14,406

 

 

 

15,299

Other assets, current

 

14,200

 

 

 

14,189

Total current assets

 

245,102

 

 

 

309,210

Property and equipment, net

 

24,403

 

 

 

23,877

Operating lease right-of-use assets, net

 

70,818

 

 

 

74,333

Marketable debt securities, available-for-sale (amortized cost of $142,322 and $145,570

 

at March 31, 2026 and December 31, 2025, respectively, and $0 allowance for credit losses)

 

141,512

 

 

 

145,701

Assets held in rabbi trust

 

13,165

 

 

 

13,476

Deferred tax assets, net

 

44,035

 

 

 

44,586

Goodwill and other intangible assets, net

 

41,172

 

 

 

41,662

Advances and loans, net

 

146,743

 

 

 

147,215

Other assets, non-current

 

28,013

 

 

 

27,120

Total assets

$

754,963

 

 

$

827,180

Liabilities and stockholders’ equity

 

 

 

Current liabilities:

 

 

 

Accounts payable and accrued expenses

$

11,241

 

 

$

11,021

Deferred compensation and commissions

 

33,707

 

 

 

57,463

Operating lease liabilities

 

18,320

 

 

 

18,796

Accrued bonuses and other employee related expenses

 

10,985

 

 

 

23,856

Other liabilities, current

 

18,275

 

 

 

10,311

Total current liabilities

 

92,528

 

 

 

121,447

Deferred compensation and commissions

 

29,371

 

 

 

35,416

Operating lease liabilities

 

56,714

 

 

 

59,459

Other liabilities, non-current

 

7,297

 

 

 

7,755

Total liabilities

 

185,910

 

 

 

224,077

Commitments and contingencies

 

 

 

 

Stockholders’ equity:

 

 

 

Preferred stock, $0.0001 par value:

 

 

 

Authorized shares – 25,000,000; issued and outstanding shares – none at March 31, 2026

 

and December 31, 2025, respectively

 

 

 

 

Common stock, $0.0001 par value:

 

 

 

Authorized shares – 150,000,000; issued and outstanding shares – 37,821,936 and

 

38,422,993 at March 31, 2026 and December 31, 2025, respectively

 

4

 

 

 

4

Additional paid-in capital

 

196,296

 

 

 

192,945

Retained earnings

 

373,270

 

 

 

409,753

Accumulated other comprehensive (loss) income

 

(517

)

 

 

401

Total stockholders’ equity

 

569,053

 

 

 

603,103

Total liabilities and stockholders’ equity

$

754,963

 

 

$

827,180

MARCUS & MILLICHAP, INC.

OTHER INFORMATION

(Unaudited)

Adjusted EBITDA Reconciliation

Adjusted EBITDA, which the Company defines as net loss before (i) interest income and other, including interest on marketable debt securities, available-for-sale and cash, cash equivalents, and restricted cash, and net realized gains (losses) on marketable debt securities, available-for-sale, (ii) interest expense, (iii) provision (benefit) for income taxes, (iv) depreciation and amortization, and (v) stock-based compensation. The Company uses Adjusted EBITDA in its business operations to evaluate the performance of its business, develop budgets and measure its performance against those budgets, among other things. The Company also believes that analysts and investors use Adjusted EBITDA as a supplemental measure to evaluate its overall operating performance. However, Adjusted EBITDA has material limitations as a supplemental metric and should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under U.S. generally accepted accounting principles (“U.S. GAAP”). The Company finds Adjusted EBITDA to be a useful management metric to assist in evaluating performance, because Adjusted EBITDA eliminates items related to capital structure, taxes and non-cash items. Considering the foregoing limitations, the Company does not rely solely on Adjusted EBITDA as a performance measure and also considers its U.S. GAAP results. Adjusted EBITDA is not a measurement of the Company’s financial performance under U.S. GAAP and should not be considered as an alternative to net loss, operating loss or any other measures calculated in accordance with U.S. GAAP. Because Adjusted EBITDA is not calculated in the same manner by all companies, it may not be comparable to other similarly titled measures used by other companies.

A reconciliation of the most directly comparable U.S. GAAP financial measure, net loss, to Adjusted EBITDA is as follows (in thousands):

 

Three Months Ended March 31,

 

2026

 

2025

Net loss

$

(3,100

)

 

$

(4,422

)

Adjustments:

 

 

 

Interest income and other (1)

 

(4,052

)

 

 

(4,038

)

Interest expense

 

153

 

 

 

187

 

Provision (benefit) for income taxes

 

934

 

 

 

(9,497

)

Depreciation and amortization

 

2,391

 

 

 

2,849

 

Stock-based compensation

 

6,616

 

 

 

6,179

 

Adjusted EBITDA

$

2,942

 

 

$

(8,742

)

(1)

Other includes net realized gains (losses) on marketable debt securities available-for-sale.

Glossary of Terms

  • Private Client Market: transactions with values from $1 million up to but less than $10 million

  • Middle Market: transactions with values from $10 million up to but less than $20 million

  • Larger Transaction Market: transactions with values of $20 million and above

  • Acquisitions: acquisition of businesses accounted for as a business combination in accordance with generally accepted accounting standards

 

Investor Relations Contact:

Investor Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Finance Consulting Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

2026 Revenue Guidance of at least $100M

Conference Call Today at 8:30 a.m. Eastern Time

QUEENSBURY, N.Y.–(BUSINESS WIRE)–
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Results

  • Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025

    • HEPZATO KIT™ revenue of $23.3 million, compared to $18.0 million in the first quarter of 2025

    • CHEMOSAT® revenue of $1.7 million, compared to $1.8 million in the first quarter of 2025

  • Gross margins of 85%, compared to 86% in the first quarter of 2025

  • Net loss of $1.1 million, compared to a net income of $1.1 million in the first quarter of 2025

  • Non-GAAP adjusted EBITDA of $3.4 million, compared to $7.6 million in the first quarter of 2025

  • Cash provided by operations of $0.9 million in the quarter; compared to $2.2 million provided by operations in the first quarter of 2025

  • Repurchased 316,023 common shares for proceeds of approximately $3.0 million in the first quarter of 2026 under the approved $25 million Share Buyback Program

  • Cash and investments of $89.3 million as of March 31, 2026

Business Highlights

  • Currently 29 active centers

  • Approximately 36% growth in HEPZATO volume in the first quarter 2026 compared to the first quarter 2025

  • Announced the publication of full results from the investigator-initiated CHOPIN randomized Phase 2 trial in The Lancet Oncology, demonstrating that adding ipilimumab and nivolumab to percutaneous hepatic perfusion significantly improved progression-free survival in metastatic uveal melanoma.

  • Announced that CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included as a recommended liver-directed regional therapy option in the newly published Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up (April 2026)

“We delivered a strong first quarter, marked by 20% volume growth over the prior quarter and a strong increase in new patient starts,” said Gerard Michel, Chief Executive Officer. “The recent publication of the full CHOPIN results in The Lancet Oncology is already having a meaningful impact on prescribing patterns, further validating HEPZATO KIT and positioning us for continued momentum and long-term value for patients and shareholders alike.”

2026 Full Year Financial Guidance

The Company’s financial outlook for fiscal year 2026:

  • Total CHEMOSAT and HEPZATO KIT revenue to be at least $100 million, reflecting an increase in HEPZATO KIT volume of at least 20% over 2025

  • Gross margins in the range of 84% to 87%

  • Positive adjusted EBITDA

First Quarter 2026 Results

Total revenue for the quarter ending March 31, 2026, was $25.0 million compared to $19.8 million for the same period in the prior year. Revenue in the quarter includes sales of $23.3 million of HEPZATO in the U.S. and $1.7 million of CHEMOSAT in Europe.

Research and development expenses for the quarter ending March 31, 2026, were $9.8 million compared to $5.0 million for the same period in the prior year. The increase is primarily due to the continued costs associated with expanding the clinical team, including the share-based compensation expense related to an increase in headcount, and continuation of the Phase 2 clinical trials evaluating HEPZATO.

Selling, general and administrative expenses for the quarter ended March 31, 2026, were $13.1 million compared to $11.3 million for the same period in the prior year. The increase is primarily due to continued commercial expansion activities including marketing-related expenses, additional personnel in the commercial team and share-based compensation expenses.

Net loss for the quarter ended March 31, 2026, was $1.1 million compared to net income of $1.1 million for the same period in the prior year.

Non-GAAP adjusted EBITDA for the quarter ended March 31, 2026 was $3.4 million compared to adjusted EBITDA of $7.6 million for the same period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.

As of March 31, 2026, the Company had $89.3 million in cash and investments, and no debt.

Conference Call Information

To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.

Event Date: Thursday, May 7, 2026

Time: 8:30 AM Eastern Time

Participant Numbers:

Toll Free: 1-800-717-1738

International: 1-646-307-1865

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1757946&tp_key=463dd4d428

A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website https://investors.delcath.com/news-events/events-and-presentations.

GAAP v. Non-GAAP Measures

Delcath’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. Delcath has provided in this release certain financial information that has not been prepared in accordance with GAAP. Delcath’s management believes that the non-GAAP adjusted EBITDA described in this release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Delcath’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Delcath’s industry. However, the non-GAAP financial measures that Delcath uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Safe Harbor / Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, including the Company’s statements regarding the possible synergy seen in the successful Phase 2 CHOPIN Trial being transferable to clinical practice; Company’s 2026 financial outlook, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company’s commercialization plans and its ability to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; the Company’s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company’s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company’s ability to obtain reimbursement for the HEPZATO KIT; and the Company’s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company’s filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

DELCATH SYSTEMS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share data)

 

March 31,

2026

 

December 31,

2025

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

41,313

 

 

$

43,454

 

Short-term investments

 

47,986

 

 

 

47,582

 

Accounts receivable

 

14,159

 

 

 

11,744

 

Inventories

 

9,808

 

 

 

10,252

 

Prepaid expenses and other current assets

 

7,003

 

 

 

6,498

 

Total current assets

 

120,269

 

 

 

119,530

 

Property, plant and equipment, net

 

3,662

 

 

 

3,166

 

Right-of-use assets

 

907

 

 

 

936

 

Total assets

$

124,838

 

 

$

123,632

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities

 

 

 

Accounts payable

$

3,463

 

 

$

2,658

 

Accrued expenses

 

7,143

 

 

 

8,191

 

Lease liabilities, current

 

92

 

 

 

101

 

Total current liabilities

 

10,698

 

 

 

10,950

 

Lease liabilities, non-current

 

815

 

 

 

835

 

Other liabilities, non-current

 

615

 

 

 

628

 

Total liabilities

$

12,128

 

 

$

12,413

 

Commitments and contingencies

 

 

 

Stockholders’ equity

 

 

 

Preferred stock, $0.01 par value; 10,000,000 shares authorized; 14,192 and 14,192 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

 

 

 

 

 

Common stock, $0.01 par value; 80,000,000 shares authorized; 34,465,087 shares and 34,691,671 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

 

344

 

 

 

347

 

Additional paid-in capital

 

641,713

 

 

 

639,145

 

Accumulated deficit

 

(529,918

)

 

 

(528,848

)

Accumulated other comprehensive income

 

571

 

 

 

575

 

Total stockholders’ equity

 

112,710

 

 

 

111,219

 

Total liabilities and stockholders’ equity

$

124,838

 

 

$

123,632

 

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share data)

 

Three months ended March 31,

 

 

2026

 

 

 

2025

 

Product revenue

$

24,994

 

 

$

19,784

 

Cost of goods sold

 

(3,736

)

 

 

(2,845

)

Gross profit

 

21,258

 

 

 

16,939

 

Operating expenses:

 

 

 

Research and development expenses

 

9,824

 

 

 

5,007

 

Selling, general and administrative expenses

 

13,071

 

 

 

11,290

 

Total operating expenses

 

22,895

 

 

 

16,297

 

Operating (loss) income

 

(1,637

)

 

 

642

 

Interest income

 

787

 

 

 

618

 

Other (expense) income

 

(58

)

 

 

4

 

(Loss) income before income taxes

 

(908

)

 

 

1,264

 

Income tax expense

 

162

 

 

 

195

 

Net (loss) income

 

(1,070

)

 

 

1,069

 

Other comprehensive income (loss):

 

 

 

Unrealized gain on investments adjustments

 

45

 

 

 

239

 

Foreign currency translation adjustments

 

(49

)

 

 

60

 

Total comprehensive (loss) income

$

(1,074

)

 

$

1,368

 

Common share data:

 

 

 

Basic (loss) income per common share

$

(0.03

)

 

$

0.03

 

Weighted average number of basic shares outstanding

 

36,021,210

 

 

 

34,642,641

 

Diluted (loss) income per common share

$

(0.03

)

 

$

0.03

 

Weighted average number of dilutive shares outstanding

 

36,021,210

 

 

 

39,511,120

 

DELCATH SYSTEMS, INC.

Reconciliation of Reported Net Income (Loss) (GAAP) to Adjusted EBITDA (NON-GAAP Measure)

(Unaudited)

(in thousands)

 

Three months ended March 31,

 

 

2026

 

 

 

2025

 

Net (loss) income

$

(1,070

)

 

$

1,069

 

Stock-based compensation expense

 

4,946

 

 

 

6,863

 

Depreciation

 

102

 

 

 

43

 

Interest income

 

(787

)

 

 

(618

)

Income tax expense

 

162

 

 

 

195

 

Adjusted EBITDA (Non-GAAP)

$

3,353

 

 

$

7,552

 

 

Investor Relations Contact:

ICR Healthcare

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Biotechnology Medical Devices Health Pharmaceutical Oncology

MEDIA:

Logo
Logo

Everest Appoints Lisa Davis to Lead North America Wholesale & Specialty Business

Everest Appoints Lisa Davis to Lead North America Wholesale & Specialty Business

HAMILTON, Bermuda–(BUSINESS WIRE)–
Everest Group, Ltd. (“Everest” or “the Company”) (NYSE: EG), a global underwriting leader providing world-class reinsurance and specialty insurance solutions, today announced the appointment of Lisa Davis as Head of North America, Wholesale & Specialty.

Ms. Davis will lead Everest’s North America Wholesale & Specialty business, overseeing underwriting strategy, distribution, and portfolio management across the region. She will report to Jason Keen, EVP and CEO of Global Wholesale & Specialty, and serve as a key member of his leadership team.

“Along with her extensive experience, Lisa brings a combination of underwriting discipline, operational leadership, and strong relationships that are critical in this environment,” said Jason Keen. “Her ability to build profitable specialty businesses, lead high-performing teams, and deepen broker relationships will be instrumental as we continue to strengthen our North America platform, deliver disciplined, profitable growth, and execute our long-term strategy.”

Ms. Davis brings more than 35 years of experience building and scaling specialty insurance businesses across wholesale markets, with deep expertise in underwriting leadership, portfolio management, and distribution strategy. Most recently, she led the build-out and expansion of Canopius’ U.S. business, delivering sustained profitable growth while significantly scaling the platform. Prior to that, she served as President and Chief Operating Officer for North America at Sompo America and held leadership roles at Zurich North America and St. Paul Companies.

About Everest

Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.

Everest common stock (NYSE: EG) is a component of the S&P 500 index.

Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.

Media: Dawn Lauer

Chief Communications Officer

908.300.7670

Investors: Matt Rohrmann

Head of Investor Relations

908.604.7343

KEYWORDS: Ireland United Kingdom Europe Bermuda Caribbean

INDUSTRY KEYWORDS: Professional Services Insurance Finance

MEDIA:

Logo
Logo

Kaltura Launches Avatar Video Production Studio, Transforming Enterprise Knowledge Into Interactive, Avatar-Led Video Experiences at Scale

Following its beta release, the generally available studio enables organizations to automatically produce videos from text, slides, or other videos at a mere fraction of the time and cost while boosting effectiveness, interactivity, and outcomes.

New York, New York, May 07, 2026 (GLOBE NEWSWIRE) — Kaltura, Inc. (Nasdaq: KLTR), the Agentic Digital Experience company, today announced the general availability of its Avatar Video Production Studio that transforms enterprise knowledge into structured, avatar-led video experiences that can be created in minutes, distributed at scale, and extended into real-time, interactive engagements. 

Organizations generate more knowledge than they can effectively activate. Content exists across webinars, training sessions, documents, and internal communications, yet much of it remains difficult to consume, repurpose, or act on at scale. The challenge is no longer creating content – it is making knowledge accessible, structured, and actionable across every organizational journey. Avatar Video Production Studio addresses this gap by enabling any business user to convert existing knowledge assets into high-quality, avatar-narrated video experiences – without filming, editing, or traditional production workflows. 

Key Capabilities 

Avatar Video Production Studio enables organizations to: 

  • Convert existing assets into structured video narratives – Transform recordings, presentations, documents, and web page URLs into concise, avatar-led video experiences automatically 
  • Generate 
    new videos
     from simple scripts – Create professional-quality video content from text-based inputs in minutes 
  • Eliminate
     traditional production workflows – Remove the need for filming, editing, scheduling, and post-production entirely 
  • Scale content creation without scaling headcount – Enable business users across departments to produce video independently and consistently
     

Measurable Business Impact 

Organizations deploying Avatar Video Production Studio can: 

  • Reduce video production time by eliminating filming, editing, and production bottlenecks – creating content in a fraction of the time required by traditional workflows (early users have reported approximately 90% reduction in production time compared to traditional video workflows). 
  • Increase content output by 3–5x across teams without adding headcount or operational overhead 
  • Accelerate time-to-publish and time-to-knowledge across the organization 
  • Scale engagement without increasing human support resources 

Unlike standalone AI video generation tools, Avatar Video Production Studio is deeply integrated into Kaltura’s broader platform – built on a proven, enterprise-grade infrastructure trusted by leading organizations across technology, education, financial services, healthcare, professional services, and media and telecom. Powering video and rich media experiences for some of the world’s largest enterprises, Kaltura’s platform supports large-scale deployments with enterprise-grade security, governance, and reliability, enabling organizations to confidently deploy AI-driven content and engagement across global operations. 

As part of this unified platform, organizations can seamlessly publish and distribute avatar-led videos across content hubs, learning environments, events, and digital touchpoints – allowing content to move beyond isolated assets and become part of orchestrated, personalized user journeys, where the right information is delivered in the right format, at the right moment, aligned with user intent and business goals. 

Video-to-Live: From Viewing to Interaction 

A primary differentiator of Avatar Video Production Studio is its Video-to-Live capability, which enables a seamless transition from recorded video to real-time interaction. Viewers can move directly from watching an avatar-led video into a live conversation with the same avatar—asking questions, exploring topics in depth, and receiving contextual guidance. This transforms video from a one-way communication format into an always-on, responsive experience that helps organizations scale engagement without scaling human support or headcount. 

Agentic, Action-Driven Experiences 

The experience extends beyond content consumption. As part of Kaltura’s Agentic Digital Experience Platform, Avatar Video connects content creation with conversational agents and journey orchestration. Avatars understand user context, intent, and organizational knowledge, guiding users toward meaningful actions including: 

  • Progressing through training or learning paths 
  • Completing onboarding steps 
  • Resolving support issues 
  • Advancing purchase or decision processes 

These interactions are adaptive, personalized, and always available – transforming passive viewing into active engagement while capturing intent signals that continuously improve content, personalize journeys, and drive measurable outcomes. 

Real-World Use Cases 

Organizations across industries are already leveraging Avatar Video Production Studio in high-impact scenarios: 

  • Sales – Teams generate concise highlight videos from long recorded meetings and share them as personalized follow-ups to reinforce key messages and accelerate deal cycles 
  • Education and Learning & Development – Teams transform lectures, training sessions, and course materials into structured, topic-specific video modules, complete with visual enhancements and b-roll to improve engagement and comprehension 
  • Internal Communications – Teams convert long town halls and leadership updates into concise video recaps, ensuring key messages are clearly delivered and easily consumed across distributed, global teams 

“We are witnessing a fundamental shift from content creation to knowledge activation,” said Ron Yekutiel, Co-Founder, Chairman, President, and CEO at Kaltura. “Organizations have vast amounts of knowledge locked inside recordings, documents, and fragmented systems. Avatar Video Production Studio unlocks that knowledge and transforms it into interactive, personalized experiences that drive engagement, understanding, and business results – at scale. With the transition from video to live, agentic interaction, we are enabling organizations to move beyond passive content delivery and into a world where every piece of content becomes an opportunity to guide, engage, and drive outcomes.” 

Avatar Video Production Studio is available today, and organizations can get started by booking a demo here. Self-serve purchasing will be available in the third quarter of 2026. 

About Kaltura 

Kaltura’s mission is to power rich, agentic digital experiences across organizational journeys for customers, employees, learners, and audiences. Its platform combines intelligent content creation, enterprise-grade content management and intelligence, and multimodal conversational engagement capabilities. Kaltura serves leading enterprises, financial institutions, educational institutions, media and telecom providers, and other organizations worldwide. For more information, visit www.kaltura.com



Nohar Zmora 

SVP, Head of Marketing 

[email protected] 

Fifth Third Closes Fannie Mae DUS® Acquisition; Strengthens Multifamily Lending Capabilities

Fifth Third Closes Fannie Mae DUS® Acquisition; Strengthens Multifamily Lending Capabilities

Bank is now one of 24 DUS® Lenders.

CINCINNATI–(BUSINESS WIRE)–
Fifth Third Bancorp (NASDAQ: FITB) announced closing of a transaction to acquire Mechanics Bank’s Delegated Underwriting and Servicing (DUS®) business line, including an experienced lending team, and a $1.8 billion unpaid principal balance servicing portfolio.

Fifth Third joins a group of just 24 lenders nationwide authorized by Fannie Mae to originate, underwrite, close, and service multifamily loans. Fifth Third is currently the ninth-largest U.S. bank, with approximately $297 billion in assets. Multifamily housing is the largest component of its commercial real estate portfolio.

“This will significantly enhance the Bank’s ability to finance multifamily housing across the United States and further strengthens our leadership in commercial real estate finance,” said John Hein, head of Commercial Real Estate at Fifth Third. “This acquisition empowers us to better support our clients and the housing needs in the communities we serve across the country.”

The US continues to face a shortage of housing. According to a U.S. Chamber of Commerce report*, “a severe shortage of over 4.7 million homes has created cascading economic and social challenges, from skyrocketing prices to reduced workforce mobility.” This capability will allow the Bank to facilitate the financing of more housing and be a part of the solution for a problem that spans a wide breadth of the housing sector.

As a cornerstone of Fannie Mae’s multifamily lending platform, the DUS program is designed to provide liquidity and stability to the housing market. Fifth Third gains direct access to Fannie Mae products and a proven servicing model by joining this program and reinforces its commitment to delivering innovative solutions for clients and advancing housing affordability.

About Fifth Third

Fifth Third is a bank that’s as long on innovation as it is on history. Since 1858, we’ve been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it’s one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere’s World’s Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation’s highest performing regional bank, but to be the bank people most value and trust.

Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank, and its common stock is traded on the NASDAQ® Global Select Market under the symbol “FITB.” Investor information and press releases can be viewed at www.53.com.

*U.S. Chamber of Commerce, The State of Housing in America, March 15, 2025

Adrienne Gutbier (Media Relations)

[email protected] | 513-534-8038

Matt Curoe (Investor Relations)

[email protected] | 513-534-2345

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Perpetuals Files Patent for Bias-Removal Architecture for AI Agents Solving The Reliability Problem Blocking Enterprise Agentic AI

Perpetuals Files Patent for Bias-Removal Architecture for AI Agents Solving The Reliability Problem Blocking Enterprise Agentic AI

  • Patent filing for unique AI-powered algorithm for identifying top-performing AI and human decision-makers, including which LLM is most accurate for a given task
  • System identifies the top 1–5% of AI models and human experts per decision type, applying patent-pending bias-removal across financial trading, clinical decision support, fraud detection, cybersecurity, and additional decision-intensive domains

SAN FRANCISCO–(BUSINESS WIRE)–
Perpetuals.com Ltd (Nasdaq: PDC), an AI-powered fintech company, has filed a U.S. patent application covering BayesShield AI, a system that identifies which AI model or human expert performs best for a specific decision, in real time. The patent addresses one of the most-cited blockers to enterprise agentic AI deployment: the gap between average benchmark performance and reliable performance on the decision in front of you.

The trailblazing and complex system is built on a simple premise: performance is not universal. Both AI models and human experts perform differently depending on the context of a decision. A model that performs well in one type of environment may underperform in another, and the same is true for human decision-makers.

Perpetuals’s new framework addresses this by continuously evaluating performance across different decision environments, or “regimes,” and learning which AI models or human experts are most effective in each. It can assess leading large language models, including ChatGPT, Claude, Gemini, and DeepSeek systems, on a task-by-task basis rather than relying on a single overall benchmark.

The patent application addresses what industry analysts have identified as the central blocker to enterprise agentic AI deployment. McKinsey’s 2026 AI Trust Maturity Survey found that security and risk concerns are now the top barrier to scaling agentic AI, with only about one-third of organizations reaching maturity in agentic AI controls. Gartner has projected that more than 40% of agentic AI projects will be canceled by 2027 due to escalating costs, unclear business value, or inadequate risk controls. Recent academic research has documented a 37% gap between lab benchmark scores and real-world production performance, the gap that BayesShield is designed to close.

Over time, the system builds a map of which models and experts are best suited to specific conditions and routes decisions to them only when those conditions are present. This enables more precise matching between problem type and decision-maker, rather than relying on averages or static rankings.

“For a decade, AI progress has been measured by which model has the best benchmark average. The agentic era has exposed that this metric doesn’t predict production performance; McKinsey, Gartner, and Deloitte are all reporting the same gap. The next edge in AI isn’t a single model that wins on average. It’s a system that knows which model, or which expert, will win in the decision in front of you,” said Patrick Gruhn, CEO of Perpetuals. “That’s what we are patenting. And it’s already running our products today.”

The approach is designed for use across a range of decision-intensive industries, including financial trading, fraud detection, cybersecurity, content moderation, health care diagnostic decision support, insurance underwriting, and legal analysis. This process is already powering many of Perpetuals’s own products, including in financial markets and the deployment of BayesShield to reduce medical diagnostic errors, with more on the way.

The patent application describes a six-step pipeline:

  • Capturing predictions in a simulated, no-risk environment

  • Tagging each prediction with the conditions in which it was made

  • Training AI models on rare but high-value cases rather than discarding them

  • Identifying the top 1–5% of performers in each situation type

  • Deploying these top performers only when conditions match their proven strengths

  • Continuously updating rankings with new performance data

About Perpetuals.com Ltd.

Perpetuals.com Ltd (NASDAQ: PDC) is a fintech company developing AI-powered trading products and prediction markets, with a global footprint across the United States, Europe, and Asia. Its mission is to reduce risk through empowering retail users with intuitive, secure, and efficient trading experiences across multiple asset classes.

Perpetuals’s proprietary trading platform, Kronos X, combines advanced AI and data analysis. The technology is trained on billions of trades, monitors market activity in real time, identifies patterns for trading and risk decisions, and provides multi-asset coverage with self‑clearing blockchain-based settlement. The company’s licensed European Multilateral Trading Facility (MTF) infrastructure and Kronos X multi‑asset exchange platform operate with full MiFID II, MiCA, DORA, and EMIR compliance.

Forward-Looking Statements: This press release contains forward-looking statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the scope and protection afforded by the provisional patent application, the expected applicability of the disclosed methodology across industries, and the anticipated benefits to the company’s intellectual property portfolio. The filing of a provisional patent application does not guarantee that any patent will issue, that any claims will be granted as filed, or that any resulting patent will provide meaningful commercial protection. Words such as “expect,” “will,” “positions,” “advancing,” “projected,” “anticipated,” and other similar expressions indicate forward-looking statements, though not all forward-looking statements contain such words. These statements reflect the company’s current view with respect to future events, are subject to risks and uncertainties that could cause actual results to differ materially, including regulatory approvals, market conditions, the ability to realize anticipated benefits of any patent that may be issued, and risks detailed in the company’s filings with the Securities and Exchange Commission, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the company, are inherently subject to significant business, economic, competitive, regulatory, political, and social uncertainties and contingencies. In addition, there can be no assurance that any patent will issue from the company’s pending application, or that any issued patent will provide protection of sufficient scope to provide meaningful competitive advantages. Should one or more of these risks or uncertainties materialize, or should the assumptions set out by the company underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. These forward-looking statements are made as of the date of this press release and the company does not undertake any obligation to update these forward-looking statements, except as required by law.

Media

Perpetuals Email: [email protected] Website: www.perpetuals.com

Investor Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Technology Blockchain Software Fintech Artificial Intelligence

MEDIA:

Logo
Logo